ERBB2 and gastric neoplasm: Molecular targeting works well in disease states that do not have a barrier to the drug and molecular signature, including trastuzumab (Herceptin), which is approved to treat certain breast and stomach cancers that overexpress human epidermal growth factor receptor 2 protein (HER-2) [35].